CDAK · Codiak Biosciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $522.0K | $13.14M | $12.70M | - | $1.16M | $890.0K | $134.0K | - | $954.0K | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $10.85M | $12.80M | $14.25M | - | $15.47M | $11.62M | $18.39M | - | $16.55M | - |
| SG&A | $6.56M | $7.36M | $6.71M | - | $7.19M | $4.36M | $4.23M | - | $5.34M | - |
| Total Operating Expenses | $21.92M | $20.16M | $20.95M | - | $22.65M | $15.98M | $22.62M | - | $21.38M | - |
| D&A | - | - | $1.08M | - | $1.40M | $900.0K | $1.03M | - | $1.10M | - |
| Operating Income | ($21.40M) | ($7.02M) | ($8.25M) | - | ($21.50M) | ($21.47M) | ($22.49M) | - | ($35.03M) | - |
| Interest Expense | $758.0K | $649.0K | $600.0K | - | $689.0K | $294.0K | $295.0K | - | $3.0K | - |
| Income Tax | - | - | - | - | - | - | - | - | $0 | - |
| Net Income | ($19.28M) | ($6.78M) | ($8.03M) | - | ($21.70M) | ($21.81M) | ($22.50M) | - | ($35.29M) | - |
| EPS - Basic | ($0.97) | - | - | - | - | - | - | - | - | - |
| EPS - Diluted | ($0.97) | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $51.76M | $41.78M | $56.49M | $76.94M | $98.58M | $113.68M | $130.27M | $88.92M | $32.06M | $14.85M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.96M | $1.13M | $1.52M | $1.84M | $2.00M | $1.78M | $2.16M | $2.02M | $2.49M | - |
| Current Assets | $61.23M | $56.01M | $69.91M | $90.17M | $103.91M | $119.32M | $134.68M | $93.76M | $52.36M | - |
| Total Assets | $134.40M | $132.71M | $150.07M | $171.67M | $158.72M | $175.27M | $191.50M | $151.34M | $115.96M | - |
| Current Liabilities | $14.46M | $12.01M | $11.54M | $27.16M | $23.10M | $20.92M | $15.54M | $17.65M | $19.75M | - |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $95.47M | $88.31M | $101.69M | $118.17M | $124.72M | $123.41M | $122.78M | $136.77M | $154.39M | - |
| Stockholders' Equity | $38.93M | $44.40M | $48.38M | $53.51M | $34.01M | $51.86M | $68.72M | $14.57M | ($170.09M) | - |
| Retained Earnings | ($359.33M) | ($340.05M) | ($333.27M) | ($325.25M) | ($341.91M) | ($320.21M) | ($298.40M) | ($288.09M) | ($270.13M) | - |
Cash Flow
| Line item | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($20.85M) | - | - | - | ($18.99M) | - | - | - |
| Investing Cash Flow | - | - | ($182.0K) | - | - | - | $56.50M | - | - | - |
| Financing Cash Flow | - | - | $589.0K | - | - | - | $18.0K | - | - | - |
| CapEx | - | - | $182.0K | - | - | - | $14.06M | - | - | - |
| Free Cash Flow | - | - | ($21.03M) | - | - | - | ($33.05M) | - | - | - |
Ratios
| Metric | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -4098.9% | -53.4% | -64.9% | - | -1857.9% | -2411.9% | -16783.6% | - | -3671.7% | - |
| EBITDA margin | - | - | -56.5% | - | -1736.9% | -2310.8% | -16016.4% | - | -3556.4% | - |
| Net margin | -3693.1% | -51.5% | -63.2% | - | -1875.7% | -2450.4% | -16792.5% | - | -3699.5% | - |
| Free cash flow margin | - | - | -165.6% | - | - | - | -24667.2% | - | - | - |
| FCF / Net income | - | - | 2.62 | - | - | - | 1.47 | - | - | - |
| R&D / Revenue | 2078.0% | 97.4% | 112.2% | - | 1336.8% | 1305.8% | 13724.6% | - | 1734.4% | - |
| SG&A / Revenue | 1257.3% | 56.0% | 52.8% | - | 621.1% | 489.7% | 3159.0% | - | 560.0% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -14.3% | -5.1% | -5.3% | - | -13.7% | -12.4% | -11.8% | - | -30.4% | - |
| Return on equity | -49.5% | -15.3% | -16.6% | - | -63.8% | -42.1% | -32.7% | - | 20.7% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 4.24 | 4.66 | 6.06 | 3.32 | 4.50 | 5.70 | 8.67 | 5.31 | 2.65 | - |
| Quick ratio | 4.24 | 4.66 | 6.06 | 3.32 | 4.50 | 5.70 | 8.67 | 5.31 | 2.65 | - |
| Cash ratio | 3.58 | 3.48 | 4.90 | 2.83 | 4.27 | 5.43 | 8.38 | 5.04 | 1.62 | - |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -28.2x | -10.8x | -13.8x | - | -31.2x | -73.0x | -76.2x | - | -11676.0x | - |
| Equity multiplier | 3.45 | 2.99 | 3.10 | 3.21 | 4.67 | 3.38 | 2.79 | 10.39 | -0.68 | - |
| Liabilities / Assets | 0.71 | 0.67 | 0.68 | 0.69 | 0.79 | 0.70 | 0.64 | 0.90 | 1.33 | - |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | 0.10 | 0.08 | - | 0.01 | 0.01 | 0.00 | - | 0.01 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -54.9% | 1377.0% | 9380.6% | - | 21.3% | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 0.5% | 67.3% | 63.3% | - | 38.6% | - | - | - | - | - |
| Net income growth (YoY) | 11.2% | 68.9% | 64.3% | - | 38.5% | - | - | - | - | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | 36.4% | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 14.5% | -14.4% | -29.6% | 267.3% | - | - | - | - | - | - |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Codiak BioSciences against the 5 most active filers in the same SIC group.